Rf Acquisition CORP Ii

RF Acquisition Corp II shareholders approved an extension to complete a business combination until August 15, 2026, following significant share redemptions.

AI drug discovery pioneer Nanyang Biologics Pte. Ltd. will merge with RF Acquisition Corp II in a $1.5 billion transaction to become a Nasdaq-listed company.

Tse Meng Ng resigns from the audit committee of RF Acquisition Corp II, effective immediately, but will remain on the board of directors.

RF Acquisition Corp II appoints Tuan Lee Low as a Class I director and chairman of the Audit Committee, effective May 1, 2025.

RF Acquisition Corp II will allow separate trading of its ordinary shares and rights, previously bundled as units, starting July 5, 2024.

RF Acquisition Corp II successfully completed its initial public offering and over-allotment option, raising a total of $115.575 million.

RF Acquisition Corp II reports Q1 2026 results, with net income of $93,702, driven by interest income, while continuing its search for a business combination.

RF Acquisition Corp II reports Q3 2025 results, detailing a proposed merger with Nanyang Biologics and a shareholder vote to extend its business combination deadline to August 2026.

RF Acquisition Corp II, a blank check company, reported increased net income for the second quarter of 2025 driven by trust account interest, but disclosed substantial doubt about its ability to continue as a going concern and ineffective disclosure controls.

RF Acquisition Corp II reports a net income of $1.02 million for the three months ended March 31, 2025, driven by interest earned on cash held in trust.

RF Acquisition Corp II reported a net income of $1.4 million for the quarter ended September 30, 2024, primarily driven by interest earned on its trust account.

RF Acquisition Corp II, a special purpose acquisition company, reported a net income of $486,608 for the period from February 5, 2024, through June 30, 2024, and outlined its plans to pursue a business combination in the Asian deep technology sector.

RF Acquisition Corp II filed its annual 10-K report, disclosing a definitive business combination agreement with Nanyang Biologics Pte. Ltd. and an extension of its deadline to August 15, 2026, following significant share redemptions.

RF Acquisition Corp II's 10-K filing details the company's share structure, redemption rights, and plans to identify a business combination target in the deep technology sector.

RF Acquisition Corp II shareholders approved an extension to complete a business combination until August 15, 2026, despite significant share redemptions.

Nanyang Biologics, an AI-driven drug discovery company, will go public via a business combination with SPAC RF Acquisition Corp II in a $1.5 billion transaction.

CEO Ng Tse Meng reports changes in beneficial ownership of RF Acquisition Corp II ordinary shares and rights, including acquisitions through derivative securities.

Alfa 24 Ltd, a 10% owner and director of RF Acquisition Corp II, reports changes in beneficial ownership, including the acquisition and disposal of ordinary shares and rights.

RF Acquisition Corp II is holding an extraordinary general meeting on August 12, 2026, to vote on proposals to extend the deadline for consummating a business combination.

RF Acquisition Corp II is holding an Extraordinary General Meeting to vote on extending its business combination deadline to August 15, 2026, to complete its merger with Nanyang Biologics.

RF Acquisition Corp II, a Cayman Islands-based blank check company, is set to launch a $100 million IPO, focusing on business combinations within the Asian deep technology sector.

RF Acquisition Corp II files an amendment to its S-1 registration statement, outlining its focus on deep technology sectors in Asia for potential business combinations.

RF Acquisition Corp II, a Cayman Islands-based blank check company, has filed an S-1 registration statement for a $100 million initial public offering, with plans to target businesses in Asia's deep technology sector.

Mizuho Financial Group, Inc. has granted power of attorney to Takahiro Katsura for executing and filing Form 13G with the SEC.

W.R. Berkley Corporation and its subsidiary, Berkley Insurance Company, have reported a 9.2% beneficial ownership stake in RF Acquisition Corp II.

Karpus Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 1,640,733 shares, representing 19.66% of the common stock of RF Acquisition Corp II.

Karpus Management, Inc. has disclosed an increased beneficial ownership of 28.66% in RF Acquisition Corp II, holding 2,391,058 common shares.

AQR Capital Management, LLC and its affiliates have disclosed a 2.04% beneficial ownership stake in RF Acquisition Corp II as of December 31, 2025.

W. R. Berkley Corporation and its subsidiary Berkley Insurance Company reported a 3.6% beneficial ownership stake in RF Acquisition Corp II as of December 31, 2025.